Gastric Cancer Therapy Industry Forecast to Hit $6.39 Billion by 2029 With a Strong 9.1% CAGR

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Growth Projections For The Gastric Cancer Therapy Market Size During 2025–2029?

The gastric cancer therapy market has experienced robust expansion in recent years. Its valuation is projected to increase from $4.12 billion in 2024 to $4.50 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 9.3%. This historical upward trend is primarily driven by factors such as the increasing prevalence of h. pylori infection, growing consumption of tobacco and alcohol, an expanding aging population, the scarcity of early diagnostic tools, and the widespread adoption of chemotherapy.

The gastric cancer therapy market is projected to expand significantly in the near future. It is set to reach $6.39 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 9.1%. This anticipated growth during the forecast period is fueled by factors such as the rise in biomarker-based therapies, an increase in combination treatment methods, escalating investment in oncology research and development, the growth of healthcare infrastructure in developing economies, and the uptake of liquid biopsies for disease monitoring. Prominent trends for this period involve the evolution of personalized medicine, a strong focus on targeted drug delivery systems, an uptick in clinical trials for innovative antibodies, the integration of AI in diagnostic imaging, and the ongoing development of combination therapies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25767&type=smp

What Are The Main Drivers Boosting The Gastric Cancer Therapy Industry’s Expansion?

The expanding occurrence of Helicobacter pylori infection is anticipated to drive forward the growth of the gastric cancer therapy market. Helicobacter pylori infection is a bacterial condition primarily affecting the stomach lining, serving as a primary cause of both chronic gastritis and gastric cancer. The rising incidence of this infection is mainly attributed to poor sanitation, where insufficient hygiene practices and polluted food or water sources facilitate its oral-oral or fecal-oral spread. Gastric cancer therapy is instrumental in diminishing the risk of gastric cancer caused by Helicobacter pylori infection through direct treatment of the infection, mitigation of related gastric inflammation and cellular harm, and the prevention of chronic gastritis progression and atrophic alterations that could lead to malignant transformation of the gastric mucosa. For instance, in November 2024, according to the report published by the Government of Canada, a Canada-based government administration, as of January 2023, the recurrence rate of H. pylori infection is estimated to be up to 19%, although it varies based on geographic region and age. Therefore, the increasing prevalence of Helicobacter pylori infection is fueling the expansion of the gastric cancer therapy market.

Which Key Segments Fueling The Gastric Cancer Therapy Market?

The gastric cancer therapy market covered in this report is segmented –

1) By Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery

2) By Drug Class: Cytotoxic Agents, Monoclonal Antibodies, Tyrosine Kinase Inhibitors, Checkpoint Inhibitors, Miscellaneous Agents

3) By Administration Route: Oral, Intravenous, Intramuscular, Subcutaneous

4) By Stage of Disease: Early Stage, Locally Advanced Stage, Metastatic Stage

5) By End User: Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Research Institutions, Home Care Settings

Subsegments:

1) By Chemotherapy: Neoadjuvant Chemotherapy (NAC), Adjuvant Chemotherapy (AC), Palliative Chemotherapy (PC), Combination Chemotherapy, Monotherapy

2) By Targeted Therapy: Human Epidermal Growth Factor Receptor 2 (HER2) Targeted Therapy, Vascular Endothelial Growth Factor (VEGF) Inhibitors, Fibroblast Growth Factor Receptor (FGFR) Inhibitors, Mesenchymal-Epithelial Transition (MET) Inhibitors, Claudin 18 Isoform 2 Inhibitors

3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Adoptive Cell Transfer, Cytokine Therapy, Combination Immunotherapy

4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Intensity-Modulated Radiation Therapy (IMRT), Three-Dimensional Conformal Radiation Therapy (3D-CRT), Brachytherapy

5) By Surgery: Endoscopic Mucosal Resection (EMR), Endoscopic Submucosal Dissection (ESD), Subtotal Gastrectomy, Total Gastrectomy, Lymphadenectomy

Which Key Trends Are Expected To Influence The Gastric Cancer Therapy Market In The Coming Years?

Leading companies in the gastric cancer therapy market are concentrating on developing novel treatments, particularly combination therapy, to enhance treatment effectiveness and patient results. This approach involves utilizing two or more treatments, such as chemotherapy, targeted therapy, or immunotherapy, concurrently to boost overall efficacy. For instance, in December 2024, BeOne Medicines Ltd., a China-based pharmaceutical company formerly known as BeiGene, secured approval from the U.S. Food and Drug Administration (FDA) for Tevimbra (tislelizumab-jsgr) when combined with platinum- and fluoropyrimidine-based chemotherapy. This approval is for the first-line management of adults with unresectable or metastatic HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, specifically those whose tumors express PD-L1 (=1). This authorization was supported by data from the Phase 3 RATIONALE-305 trial, which indicated that the combination therapy significantly extended median overall survival to 15.0 months, compared to 12.9 months observed with chemotherapy alone, signifying a 20% reduction in the risk of death. This pivotal achievement highlights an expanding trend among major pharmaceutical entities to invest in innovative, multimodal treatment strategies that integrate immunotherapy with conventional chemotherapy regimens to improve clinical outcomes, delay disease progression, and elevate survival rates in patients with advanced gastric cancer.

Which Major Firms Are Strengthening Their Position In The Gastric Cancer Therapy Industry?

Major companies operating in the gastric cancer therapy market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Astellas Pharma Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., BeiGene Ltd., Celltrion Healthcare Co. Ltd., Hutchison MediPharma Limited, Shanghai Henlius Biotech Inc., Imugene Limited, LintonPharm Co. Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/gastric-cancer-therapy-global-market-report

How Does The Gastric Cancer Therapy Market Perform Across Key Geographic Regions?

North America was the largest region in the gastric cancer therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric cancer therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Gastric Cancer Therapy Market Report:

https://www.thebusinessresearchcompany.com/customise?id=25767&type=smp

Browse Through More Reports Similar to the Global Gastric Cancer Therapy Market 2025, By The Business Research Company

Gastric Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Gastric Cancer Diagnostic Procedure Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastric-cancer-diagnostic-procedure-global-market-report

Intestine Cancer Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/intestine-cancer-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795